findmyKOL
Clinical trialNCT03281681WithdrawnPhase 1/PHASE2Interventional

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

SponsorDelMar Pharmaceuticals, Inc.Enrollment0Ovarian Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • St. Joseph'S Hospital and Medical Center

    Phoenix, Arizona, United States

  • Henry Ford Hospital

    Detroit, Michigan, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dianhydrogalactitol
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2021
Primary completion
31 Mar 2022
Completion
30 Sept 2022
Last update posted
18 Oct 2019
Registered enrollment
0
Registry id
NCT03281681
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.